Home » Stocks » Pacific Biosciences of California

Pacific Biosciences of California, Inc. (PACB)

Stock Price: $5.75 USD 0.14 (2.50%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $5.70 -0.05 (-0.87%) Aug 14, 7:43 PM

Stock Price Chart

Key Info

Market Cap 887.85M
Revenue (ttm) 82.52M
Net Income (ttm) -51.04M
Shares Out 154.41M
EPS (ttm) -0.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $5.75
Previous Close $5.61
Change ($) 0.14
Change (%) 2.50%
Day's Open 5.50
Day's Range 5.46 - 5.79
Day's Volume 1,744,090
52-Week Range 2.20 - 5.94

More Stats

Market Cap 887.85M
Enterprise Value 811.85M
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 154.41M
Float 151.00M
EPS (basic) -0.33
EPS (diluted) -0.33
FCF / Share 0.10
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 1.66%
Payout Ratio n/a
Shares Short 17.85M
Short Ratio 18.18
Short % of Float 12.05%
Beta 1.68
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 60.28
PS Ratio 10.76
PB Ratio 20.59
Revenue 82.52M
Operating Income -102.26M
Net Income -51.04M
Free Cash Flow 14.73M
Net Cash 76.00M
Net Cash / Share 0.49
Gross Margin 41.90%
Operating Margin -123.93%
Profit Margin -61.80%
FCF Margin 17.85%
ROA -28.68%
ROE -87.14%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 2
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$5.25*
(-8.70% downside)
Low
5.00
Current: $5.75
High
6.00
Target: 5.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue90.8978.6393.4790.7192.7860.5928.1825.9833.861.67
Revenue Growth15.6%-15.88%3.04%-2.23%53.12%115.02%8.46%-23.27%1922.88%-
Gross Profit34.5825.1034.6644.1653.4523.406.420.9413.031.67
Operating Income-101-101-89.78-71.24-29.13-62.85-77.54-94.34-110-140
Net Income-84.13-103-92.19-74.38-31.70-66.16-79.29-94.47-109-140
Shares Outstanding15313510689.1575.6170.4862.7855.7353.879.94
Earnings Per Share-0.55-0.76-0.87-0.83-0.42-0.94-1.26-1.69-2.03-14.10
Operating Cash Flow-78.31-66.43-67.52-67.93-47.89-51.47-29.83-76.82-103-122
Capital Expenditures-2.84-1.85-10.39-8.20-2.97-1.61-0.91-1.70-9.28-5.26
Free Cash Flow-81.15-68.28-77.91-76.13-50.86-53.08-30.74-78.53-112-127
Cash & Equivalents49.1010262.8771.9882.27101113101177284
Total Debt61.6714.6613.6416.1114.9513.9913.352.792.933.04
Net Cash / Debt-12.5787.7049.2455.8767.3287.3699.1897.79175281
Assets148170144138131124136130218306
Liabilities93.0756.2157.9853.2257.5769.4467.0120.3026.8525.88
Book Value54.9211486.1084.6773.5454.9569.18109191280
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Pacific Biosciences of California, Inc.
Country United States
Employees 404
CEO Michael W. Hunkapiller

Stock Information

Ticker Symbol PACB
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: PACB
IPO Date October 27, 2010

Description

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and exonucleases. In addition, it provides binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprises reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences has collaboration with Asuragen to develop assays for carrier screening and other applications based on SMRT sequencing technology and AmplideX PCR chemistry. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.